Applied Microbiology and Biotechnology

, Volume 102, Issue 24, pp 10353–10359 | Cite as

Retrospective evaluation of in vitro effect of gentamicin B1 against Fusarium species

  • Gaspar BanfalviEmail author


The in vitro susceptibility of gentamicin fractions against Fusarium growth was the subject of this retrospective study. Fusariosis was earlier an exceptionally rare human disease and an unrealistic idea to treat soil saprophytes and plant pathogens with expensive antibiotics such as gentamicins or their minor components. Disseminated fusariosis is now the second most frequent lethal fungal infection after aspergillosis especially in neutropenic patients with hematologic malignancy. Results of this study obtained between May and November 1973 were interesting but not practicable and remained unpublished. Seven Fusarium and 28 other fungal strains were tested for their susceptibility to gentamicin B1. The anti-Fusarium activity of gentamicin B1 was between 0.2 and 3.1 μg/ml minimum inhibitory concentration (MIC) values. The MIC values of clotrimazol and amphotericin B against Fusarium species were significantly higher, 3.1–12.5 μg/ml and 3.1–50 μg/ml, respectively. Gentamicin B1 and its structurally related congeners including hygromycin B, paromomycin, tobramycin (nebramycin factor 5′), nebramycin (nebramycin factor 4), and sisomicin exerted strong in vitro inhibition against Fusarium species between 0.2 and 12.5 μg/ml concentrations. The antibacterial MIC concentration of gentamicin B1 tested on 20 bacterial strains ranged between 0.1 and 50 μg/ml. Gentamicin B1, a minor fraction of the gentamicin complex, inhibited effectively the growth of Gram-positive (Staphylococcus, Streptococcus, Bacillus subtilis) bacteria and Gram-negative (Escherichia coli, Salmonella, Proteus, Pseudomonas) pathogens. Gentamicins and related aminoglycoside antibiotics are used in medical practice. It is proposed that due to the increasing incidence of fusariosis and drug resistance, gentamicin components, particularly minor fraction B1 and related aminoglycoside antibiotics, could be tested for their in vivo activity against fusariosis and aspergillosis either alone or in combination with other antifungal agents.


Fusariosis Aminoglycoside antibiotics Gentamicins Anti-Fusarium antibiotics Treatment of fusariosis 



The author is grateful to Dr. Janos Berdy, Department of Preparative Chemistry, Research Institute of Pharmaceutical Chemistry, who performed the chemical analysis of gentamicin fractions and provided them to the author for antibiotic tests. Gratitude is expressed to Dr. István Koczka, head of the Department of Department of Chemotherapeutics and Antibiotics, for permitting the use of collections of fungal and bacterial strains. The technical assistance of Mrs. Laszlo Ando and Mrs. Otto Szabo is gratefully acknowledged.

Compliance with ethical standards

Conflict of interest

The author declares that he has no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by the author.

Supplementary material

253_2018_9407_MOESM1_ESM.pdf (499 kb)
ESM 1 (PDF 499 kb)


  1. Ahmad Rather I, Seo BJ, Rejish Kumar VJ, Choi UH, Choi KH, Lim JH, Park YH (2013) Isolation and characterization of a proteinaceous antifungal compound from Lactobacillus plantarum YML007 and its application as a food preservative. Lett Appl Microbiol 57:69–76. CrossRefPubMedGoogle Scholar
  2. Al-Hatmi AMS, Meis JF, Sybren de Hoog G (2016) Fusarium: Molecular diversity and intrinsic drug resistance. PLoS Pathog 12:e1005464. CrossRefGoogle Scholar
  3. Banfalvi G (2018) Improved and adopted murine models to combat pulmonary aspergillosis. Appl Microbiol Biotechnol http//:doi: 10.1007/s00253-018-9161-8. [Epub ahead of print] Review, 102, 6865, 6875CrossRefGoogle Scholar
  4. Baradaran-Heravi A, Niesser J, Balgi AD, Choi K, Zimmerman C, South AP, Anderson HJ, Strynadka NC, Bally MB, Roberge M (2017) Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity. Proc Natl Acad Sci U S A 114:3479–3484. CrossRefPubMedPubMedCentralGoogle Scholar
  5. Bera S, Zhanel GG, Schweizer F (2010) Evaluation of amphiphilic aminoglycoside-peptide triazole conjugates as antibacterial agents. Bioorg Med Chem Lett 20:3031–3035. CrossRefPubMedGoogle Scholar
  6. Bérdy J, Pauncz JK, Vajna ZM, Horváth G, Gyimesi J, Koczka I (1977) Metabolites of gentamicin-producing Micromonospora species I. Isolation and identification of metabolites. J Antibiot (Tokyo) 30:945–954CrossRefGoogle Scholar
  7. Berthiller F, Crews C, Dall’Asta C, Saeger SD, Haesaert G, Karlovsky P, Oswald IP, Seefelder W, Speijers G, Stroka J (2013) Masked mycotoxins: a review. Mol Nutr Res 57:165–186. CrossRefGoogle Scholar
  8. Boutati EI, Anaissie EJ (1997) Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood 90:999–1008PubMedGoogle Scholar
  9. Byrne KM, Kershner AS, Maehr H, Marquez JA, Schaffner CP (1977) Separation of gentamicin C-complex into five components by CRAIG distribution. J Chromatogr 131:191–203CrossRefGoogle Scholar
  10. Chang C-WT, Takemoto JY (2014) Antifungal amphiphilic aminoglycosides. MedChemComm 5:1048–1057. CrossRefPubMedPubMedCentralGoogle Scholar
  11. Chodosh J, Miller D, Tu EZ, Culbertson WW (2000) Tobramycin-responsive Fusarium oxysporum keratitis. Can J Ophthalmol 35:29–30CrossRefGoogle Scholar
  12. Cocuroccia B, Gaido J, Gubinelli E, Annessi G, Girolomoni G (2003) Localized cutaneous hyalohyphomycosis caused by a Fusarium species infection in a renal transplant patient. J Clin Microbiol 41:905–907. CrossRefGoogle Scholar
  13. Cortés-Zavaleta O, López-Malo A, Hernández-Mendoza A, García HS (2014) Antifungal activity of lactobacilli and its relationship with 3-phenyllactic acid production. Int J Food Microbiol 173:30–35. CrossRefPubMedGoogle Scholar
  14. Crabol Y, Lortholary O (2014) Invasive mold infections in solid organ transplant recipients. Scientifica (Cairo) 2014:821969–821917. CrossRefGoogle Scholar
  15. Daniels PJL, Luce C, Nagabushan TL, Jaret RS, Schumacher D, Reimann H, Ilavsky J (1975) The gentamicin antibiotics. 6. Gentamicin C2b, an aminoglycoside antibiotic produced by Micromonospora purpurea mutant JI-33. J Antibiotics 28:35–41CrossRefGoogle Scholar
  16. Daniels PJL, Kugelman M, Mallams AK, Tkach RW, Vernay HF, Weinstein J, Jehaskel A (1971) Mass spectral studies on aminocyclitol antibiotics. Chem Commun 1971:1629–1631. CrossRefGoogle Scholar
  17. Day S, Lalitha P, Haug S, Fothergill AW, Cevallos V, Vijayakumar R, Prajna NV, Acharya NR, McLeod SD, Lietman TM (2009) Activity of antibiotics against Fusarium and Aspergillus. Br J Ophthalmol 93:116–119. CrossRefPubMedGoogle Scholar
  18. Dignani MC, Anaissie E (2004) Human fusariosis. Clin Microbiol Infect 10 Suppl 1:67–75CrossRefGoogle Scholar
  19. Dogi CA, Fochesato A, Armando R, Pribull B, de Souza MM, da Silva Coelho I, Araújo de Melo D, Dalcero A, Cavaglieri L (2013) Selection of lactic acid bacteria to promote an efficient silage fermentation capable of inhibiting the activity of Aspergillus parasiticus and Fusarium gramineraum and mycotoxin production. J Appl Microbiol 114:1650–1660. CrossRefPubMedGoogle Scholar
  20. Forster RK, Rebell G, Wilson LA (1975) Dematiaceous fungal keratitis. Br J OphthalmoI1975 59:372–376. CrossRefGoogle Scholar
  21. Gadó I, Bérdy J, Koczka I, Horváth I, Járay M, Zlatos G (1975) Gentamicin antibiotics. Hungarian patent 168,778, Dec. 30, 1973; C.A. 85:19066, 1975Google Scholar
  22. Ghannoum MA, Rice LB (1999) Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12:501–517CrossRefGoogle Scholar
  23. Guarner J, Brandt ME (2011) Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev 24:247–280. CrossRefPubMedPubMedCentralGoogle Scholar
  24. Gupta AK, Tomas E (2003) New antifungal agents. Dermatol Clin 21:565–576. CrossRefPubMedGoogle Scholar
  25. Haque AK (2018) 12. Fungal diseases in pulmonary pathology (Second Edition), Dani S. Zander and Carol F. Farver (Eds) Elsevier, Oxford, UK, pp. 217–243Google Scholar
  26. Ho DY, Lee JD, Rosso F, Montoya JG (2007) Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses 50:227–231. CrossRefPubMedGoogle Scholar
  27. Kanafani ZA, Perfect JR (2008) Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 46:120–128. CrossRefPubMedGoogle Scholar
  28. Kawakami H, Inuzuka H, Hori N, Takahashi N, Ishida K, Mochizuki K, Ohkusu K, Muraosa Y, Watanabe A, Kamei K (2015) Inhibitory effects of antimicrobial agents against Fusarium species. Med Mycol 53:603–611. CrossRefPubMedGoogle Scholar
  29. Khan N, Maymon M, Hirsch AM (2017) Combating Fusarium infection using Bacillus-based antimicrobials. Microorganisms 5:75. CrossRefGoogle Scholar
  30. Lass-Flörl C, Cuenca-Estrella M (2017) Changes in the epidemiological landscape of invasive mould infections and disease. J Antimicrob Chemother. 72(suppl 1):i5–i11. CrossRefGoogle Scholar
  31. Lee HB, Kim Y, Kim JC, Choi GJ, Park SH, Kim CJ, Jung HS (2005) Activity of some aminoglycoside antibiotics against true fungi, Phytophthora and Pythium species. J Appl Microbiol 99:836–843. CrossRefPubMedGoogle Scholar
  32. Lin L, Wagner MC, Cocklin R, Kuzma A, Harrington M, Molitoris BA, Goebl MG (2011) The antibiotic gentamicin inhibits specific protein trafficking functions of the Arf1/2 family of GTPases. Antimicrob Agents Chemother 55:246–254. CrossRefPubMedGoogle Scholar
  33. Maehr H, Schaffner CP (1967) The chemistry of the gentamicins. 1. Characterization and gross structure gentamicin A. J Am Chem Soc 89:6787–6788CrossRefGoogle Scholar
  34. Muñoz P, Guinea J, Bouza E (2006) Update on invasive aspergillosis: clinical and diagnostic aspects. Clin Microbiol Infect (12 Suppl 7):24–39,, 12CrossRefGoogle Scholar
  35. Myers DR, DeFehr J, Bennet WM, Porter GA, Olsen GD (1978) Gentamicin binding to serum and plasma proteins. Clin Pharmacol Ther 23:356–360CrossRefGoogle Scholar
  36. Nagabushan TL, PJL D, Turner WN, Morton JB (1975) The gentamicin antibiotics. 7. Structure of the gentamicin antibiotics Al, A3 and A4. J Org Chem 40:2830–2834CrossRefGoogle Scholar
  37. Nucci M, Anaissie E (2002) Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 35:909–920. CrossRefPubMedGoogle Scholar
  38. Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C, Mangini C, Simões BP, Colombo AL, Vaz J, Levy CE, Costa S, Moreira VA, Oliveira JS, Paraguay N, Duboc G, Voltarelli JC, Maiolino A, Pasquini R, Souza CA (2003) Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 98:315–319. CrossRefGoogle Scholar
  39. Odds FC, Brown AJ, Gow NA (2003) Antifungal agents: mechanisms of action. Trends Microbiol 11:272–279CrossRefGoogle Scholar
  40. Oukhouia M, Sennouni CI, Jabeur I, Hamdani H, Remmal A (2017) In-vitro study of anti-Fusarium effect of thymol, carvacrol, eugenol and menthol. J Plant Pathol Microbiol 8:10. CrossRefGoogle Scholar
  41. Raab WP, Windisch J (1973) Antagonism of neomycin by heparin. Further observations on the anaphylactoid activity of neomycin. Arzneimittelforschung 23:1326–1328PubMedGoogle Scholar
  42. Regamey C, Schaberg D, Kirby WM (1972) Inhibitory effect of heparin on gentamicin concentrations in blood. Antimicrob Agents Chemother 1:329–332CrossRefGoogle Scholar
  43. Stiles J, Penkar S, Plocková M, Chumchalová J, Bullerman LB (2002) Antifungal activity of sodium acetate and Lactobacillus rhamnosus. J Food Prot 65:1188–1191CrossRefGoogle Scholar
  44. Szigeti ZM, Talas L, Palicz Z, Szentesi P, Hargitai Z, Csernoch L, Balla J, Pocsi I, Banfalvi G, Szeman-Nagy G (2018) Murine model to follow hyphal development in invasive pulmonary aspergillosis. Appl Microbiol Biotechnol 102:2817–2825. CrossRefPubMedGoogle Scholar
  45. Wagman GH, Marquez JA, Bailey JV, Cooper D, Weinstein J, Tkach R, Daniels P (1972) Chromatographic separation of some minor components of the gentamicin complex. J Chromatogr 70:71–73CrossRefGoogle Scholar
  46. Weinstein MJ, Luedemann GM, Oden EM, Wagman GH, Rosselet JP, Marquez JA, Coniglio CT, Charney W, Herzog HL, Black J (1963) Gentamicin, a new antibiotic complex from Micromonospora. J Med Chem 6:463–464CrossRefGoogle Scholar
  47. Wiederhold NP (2017) Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist 10:249–259. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Biotechnology and Microbiology, Faculty of Science and TechnologyUniversity of DebrecenDebrecenHungary

Personalised recommendations